Last 12 months
Inside the activity.
1 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC |
Guindo ChirfiEVP Glob. Prod Strat and Comm
|
OtherRestricted Stock Unit · Derivative | 693 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · derivative · entry 5 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 693 shares Expires 2020-12-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC |
Guindo ChirfiEVP Glob. Prod Strat and Comm
|
Exercise / conversionRestricted Stock Unit · Derivative | 481 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 693 Underlying: Common Stock · 481 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC |
Guindo ChirfiEVP Glob. Prod Strat and Comm
|
Tax withholdingCommon Stock | 214 | $243.16 | $52,036.24 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · nonDerivative · entry 3 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,790 Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC |
Guindo ChirfiEVP Glob. Prod Strat and Comm
|
Exercise / conversionCommon Stock | 481 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · nonDerivative · entry 2 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 22:41 UTC |
Guindo ChirfiEVP Glob. Prod Strat and Comm
|
Tax withholdingCommon Stock | 348 | $243.16 | $84,619.68 |
DisclosureSEC source: 0001127602-20-030492 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP Glob. Prod Strat and Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,523 Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 21:57 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
PurchaseCommon Stock | 3,100 | $241.31 | $748,046.74 |
DisclosureSEC source: 0001127602-20-030238 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,810.286 F1 · balance_after: Includes 84.965 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2020. Read SEC document |
| November 04, 2020 Filed Nov 7, 2020 02:39 UTC |
Sandrock AlfredEVP, Research & Development
|
SaleCommon Stock | 1,500 | $350.00 | $525,000.00 |
DisclosureSEC source: 0001127602-20-028410 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,066.2101 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 84.965 shares acquired under the Biogen Inc. employee stock purchase plan on March 31, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:17 UTC |
McDonnell Michael R.EVP, Chief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 16,090 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-024721 · form4.xml · derivative · entry 2 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,090 Underlying: Common Stock · 16,090 shares Expires 2023-09-01 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average closing stock price for the 30 calendar days following and including the grant date and 30 calendar days prior to and including such vesting date]). Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:17 UTC |
McDonnell Michael R.EVP, Chief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 8,045 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-024721 · form4.xml · derivative · entry 1 MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,045 Underlying: Common Stock · 8,045 shares Expires 2023-09-01 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 09/01/2020. Read SEC document |
| August 03, 2020 Filed Feb 9, 2021 21:15 UTC |
Posner Brian SDirector
|
GiftCommon Stock | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004680 · form5.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,760 Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC |
Gregory GingerEVP, Human Resources
|
OtherRestricted Stock Unit · Derivative | 216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · derivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 216 shares Expires 2020-08-01 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 212 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · derivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216 Underlying: Common Stock · 212 shares Expires 2020-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC |
Gregory GingerEVP, Human Resources
|
Tax withholdingCommon Stock | 95 | $274.69 | $26,095.55 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,691.3603 Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC |
Gregory GingerEVP, Human Resources
|
Exercise / conversionCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,786.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC |
Gregory GingerEVP, Human Resources
|
Tax withholdingCommon Stock | 128 | $274.69 | $35,160.32 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,574.3603 F1 · balance_after: Includes 15.4542 shares, 69.717 shares and 14.1891 shares acquired under the Biogen Inc. employee stock purchase plan on 12/31/2019, 3/31/2020 and 6/30/2020, respectively. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:42 UTC |
Kramer RobinVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 755 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-021183 · form4.xml · derivative · entry 2 Kramer Robin · CIK 0001609222 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755 Underlying: Common Stock · 755 shares Expires 2023-07-01 F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:24 UTC |
SHERWIN STEPHEN ADirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019033 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,328 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:23 UTC |
Rowinsky Eric KDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019032 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,069 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:21 UTC |
Posner Brian SDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019031 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,885 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:19 UTC |
PANGIA ROBERT WDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019029 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,632 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:20 UTC |
PAPADOPOULOS STELIOSDirector
|
GrantCommon Stock | 1,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019030 · form4.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,565 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:16 UTC |
Mantas Jesus BDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019025 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,045 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:17 UTC |
Mulligan RichardDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019027 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,954 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:15 UTC |
LEAMING NANCYDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019023 · form4.xml · nonDerivative · entry 1 LEAMING NANCY · CIK 0001265751 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,988 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:14 UTC |
HAWKINS WILLIAM ADirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019021 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,045 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:13 UTC |
DORSA CAROLINEDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019019 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,097 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:09 UTC |
DENNER ALEXANDER JDirector
|
GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019014 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,954 Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC |
SHERWIN STEPHEN ADirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,355 | Not disclosed Strike: $59.82 | Not disclosed |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · derivative · entry 6 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,355 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4 · derivative.exercise_price: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d). F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · shares: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · price: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · derivative.underlying_shares: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC |
SHERWIN STEPHEN ADirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,923 | Not disclosed Strike: $59.82 | Not disclosed |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · derivative · entry 5 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,923 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4 · derivative.exercise_price: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d). F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The stock options become exercisable in three (3) equal annual installments commencing one year after the grant date of 03/22/2010. F2 · derivative.underlying_shares: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC |
SHERWIN STEPHEN ADirector
|
SaleCommon Stock | 270 | $295.29 | $79,728.30 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 4 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,438 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC |
SHERWIN STEPHEN ADirector
|
Exercise / conversionCommon Stock | 1,355 | $58.46 | $79,213.30 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 3 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · shares: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · price: This option was previously reported as covering 1,325 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC |
SHERWIN STEPHEN ADirector
|
SaleCommon Stock | 2,164 | $295.22 | $638,845.26 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 2 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,353 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 22:56 UTC |
SHERWIN STEPHEN ADirector
|
Exercise / conversionCommon Stock | 10,923 | $58.46 | $638,558.58 |
DisclosureSEC source: 0001127602-20-010505 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 10,675 shares at an exercise price of $59.82 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
OtherRestricted Stock Unit · Derivative | 333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · derivative · entry 5 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionRestricted Stock Unit · Derivative | 441 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · derivative · entry 4 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333 Underlying: Common Stock · 441 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 130 | $333.00 | $43,290.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · nonDerivative · entry 2 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,542.264 Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:13 UTC |
Galdes AlphonseEVP Pharmaceutical Oper & Tech
|
Exercise / conversionCommon Stock | 441 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006546 · form4.xml · nonDerivative · entry 1 Galdes Alphonse · CIK 0001789471 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672.264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:17 UTC |
Sandrock AlfredEVP, Research & Development
|
OtherRestricted Stock Unit · Derivative | 915 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006549 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 915 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:17 UTC |
Sandrock AlfredEVP, Research & Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,213 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006549 · form4.xml · derivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915 Underlying: Common Stock · 1,213 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:17 UTC |
Sandrock AlfredEVP, Research & Development
|
Tax withholdingCommon Stock | 538 | $333.00 | $179,154.00 |
DisclosureSEC source: 0001127602-20-006549 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,481.2451 Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:17 UTC |
Sandrock AlfredEVP, Research & Development
|
Exercise / conversionCommon Stock | 1,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006549 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,019.2451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
OtherRestricted Stock Unit · Derivative | 3,657 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,657 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,847 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,657 Underlying: Common Stock · 4,847 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 2,150 | $333.00 | $715,950.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,625.321 Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 4,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006552 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,775.321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
OtherRestricted Stock Unit · Derivative | 1,171 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006544 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,171 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,553 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006544 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common Stock · 1,553 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Tax withholdingCommon Stock | 689 | $333.00 | $229,437.00 |
DisclosureSEC source: 0001127602-20-006544 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,572 Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
Exercise / conversionCommon Stock | 1,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006544 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:25 UTC |
ALEXANDER SUSAN HEVP Chief Legal Off & Corp Sec
|
OtherRestricted Stock Unit · Derivative | 1,803 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005772 · form4.xml · derivative · entry 12 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,682 Underlying: Common Stock · 1,803 shares Expires 2022-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.